Morgan Stanley Fennec Pharmaceuticals Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Morgan Stanley holds 254,218 shares of FENC stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

254,218

Previous 296,613 14.29%

Holding current value

$2.09 Million

Previous $1.81 Million 16.83%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$5.01 - $8.4 $212,398 - $356,118	-42,395 Reduced 14.29%	254,218 $2.11 Million
Q1 2025 May 15, 2025	SELL	$5.54 - $7.02 $275,687 - $349,336	-49,763 Reduced 14.37%	296,613 $1.81 Million
Q4 2024 Feb 14, 2025	BUY	$3.99 - $6.37 $789,676 - $1.26 Million	197,914 Added 133.31%	346,376 $2.19 Million
Q3 2024 May 14, 2025	BUY	$4.85 - $6.73 $224,928 - $312,117	46,377 Added 45.43%	148,462 $742,000
Q3 2024 Nov 14, 2024	BUY	$4.85 - $6.73 $224,928 - $312,117	46,377 Added 45.43%	148,462 $742,000
Q2 2024 May 14, 2025	SELL	$6.02 - $10.99 $1.47 Million - $2.68 Million	-244,291 Reduced 70.53%	102,085 $623,000
Q2 2024 Oct 17, 2024	BUY	$6.02 - $10.99 $168,529 - $307,665	27,995 Added 37.79%	102,085 $623,000
Q2 2024 Aug 14, 2024	BUY	$6.02 - $10.99 $168,529 - $307,665	27,995 Added 37.79%	102,085 $623,000
Q1 2024 Oct 17, 2024	SELL	$8.82 - $11.12 $246,915 - $311,304	-27,995 Reduced 27.42%	74,090 $823,000
Q1 2024 Aug 16, 2024	SELL	$8.82 - $11.12 $26,892 - $33,904	-3,049 Reduced 3.95%	74,090 $823,000
Q1 2024 May 15, 2024	SELL	$8.82 - $11.12 $26,892 - $33,904	-3,049 Reduced 3.95%	74,090 $823,000
Q4 2023 Aug 16, 2024	SELL	$6.48 - $11.61 $161,650 - $289,623	-24,946 Reduced 24.44%	77,139 $865,000
Q4 2023 Feb 13, 2024	BUY	$6.48 - $11.61 $224,719 - $402,623	34,679 Added 81.67%	77,139 $865,000
Q3 2023 Nov 15, 2023	SELL	$7.15 - $8.94 $130,115 - $162,690	-18,198 Reduced 30.0%	42,460 $318,000
Q2 2023 Aug 14, 2023	BUY	$7.27 - $9.82 $18,065 - $24,402	2,485 Added 4.27%	60,658 $535,000
Q1 2023 May 15, 2023	BUY	$7.38 - $10.35 $94,441 - $132,448	12,797 Added 28.2%	58,173 $483,000
Q4 2022 Feb 14, 2023	BUY	$7.63 - $10.22 $71,065 - $95,189	9,314 Added 25.83%	45,376 $435,000
Q3 2022 Nov 14, 2022	SELL	$5.71 - $8.54 $24,433 - $36,542	-4,279 Reduced 10.61%	36,062 $292,000
Q2 2022 Oct 27, 2022	SELL	$5.17 - $6.33 $50,867 - $62,280	-9,839 Reduced 19.61%	40,341 $225,000
Q2 2022 Aug 15, 2022	SELL	$5.17 - $6.33 $50,867 - $62,280	-9,839 Reduced 19.61%	40,341 $225,000
Q1 2022 Oct 27, 2022	BUY	$4.29 - $6.08 $42,209 - $59,821	9,839 Added 24.39%	50,180 $281,000
Q1 2022 May 13, 2022	BUY	$4.29 - $6.08 $39,343 - $55,759	9,171 Added 22.36%	50,180 $281,000
Q4 2021 Feb 14, 2022	BUY	$3.89 - $10.01 $101 - $260	26 Added 0.06%	41,009 $180,000
Q3 2021 Nov 15, 2021	BUY	$6.51 - $9.62 $266,799 - $394,256	40,983 New	40,983 $386,000

Others Institutions Holding FENC

# of Institutions

Shares Held

14.2M

Call Options Held

10K

Put Options Held

83.8K

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $214M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account